Neurofilament test shows promise but still needs work for everyday MS care

A new analysis questions whether neurofilament light chain—a blood marker used to track multiple sclerosis severity—is ready to replace traditional clinical measures in routine practice. The finding matters to drug developers and health systems betting on blood tests to simplify MS monitoring and cut healthcare costs.

Originaltitel: Are neurofilament light chain levels ready for routine clinical use? – Commentary